Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 1:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
HSV Encephalitis
Interventions
To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Conditions
Venezuelan Equine Encephalomyelitis
Interventions
0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fort Deterick, Maryland
Conditions
Encephalitis
Interventions
Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Princeton, New Jersey
Completed No phase listed Observational

A Case Report of NMDAR Encephalopathy

NCT06915103
Conditions
Anti-NMDA Receptor Encephalitis, Mature Teratoma, Paraneoplastic Syndromes
Interventions
Magnetic Resonance Imaging (MRI), Salpingo-oophorectomy
Diagnostic Test · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
34 Years to 34 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Japanese Encephalitis
Interventions
Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
17 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
Interventions
Placebo, EG-501
Drug
Lead sponsor
Evergreen Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
BIIB091, DRF, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
23
States / cities
Scottsdale, Arizona • Berkeley, California • Orange, California + 20 more
Recruiting No phase listed Observational

CoMind Early Feasibility Study

NCT06368648
Conditions
Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage, Encephalitis, Encephalopathy, Hydrocephalus, Stroke, Autoregulation
Interventions
Not listed
Lead sponsor
CoMind Technologies Limited
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Sacramento, California • Wilmington, Delaware • Washington D.C., District of Columbia + 13 more
Conditions
HIV Associated Neurocognitive Disorder, HIV Dementia, HIV Encephalitis, Healthy
Interventions
SV2A PET, TSPO PET
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Completed No phase listed Observational Accepts healthy volunteers

Control of Leukocyte Function

NCT03027232
Conditions
Inflammation, Brain
Interventions
No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Meningoencephalitis, Other Syndromes Requiring Lumbar Puncture in Emergency Department
Interventions
no intervention
Other
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
3 Months and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Sylmar, California
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Infectious Metabolic Encephalopathy, Ischemic Stroke, Seizure, Viral Encephalitis, Small and Large Vessel
Interventions
keypresses
Behavioral
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Venezuelan Equine Encephalitis
Interventions
VEE 3526
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Autoimmune Encephalitis, Encephalitis
Interventions
Inebilizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)

NCT01031537
Conditions
Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus, NSI Protein, Flavivirus
Interventions
FSME-IMMUN 0.5ml Baxter
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • Hamilton, Montana
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Interferon alfa-2b, Zidovudine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Conditions
Equine Encephalitis
Interventions
MVA-BN-WEV Dose 1, MVA-BN-WEV Dose 2, MVA-BN-WEV Dose 3
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Leucovorin calcium, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Conditions
Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System, Limbic Encephalitis
Interventions
IVIG
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
Interventions
V4020
Biological
Lead sponsor
Medigen, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 2 Interventional Results available

Efficacy of Ocrelizumab in Autoimmune Encephalitis

NCT03835728
Conditions
Autoimmune Encephalitis
Interventions
Ocrelizumab, Saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas